Janco, Miro
Rynkiewicz, Michael J.
Li, Liang
Hook, Jeff
Eiffe, Eleanor
Ghosh, Anita
Böcking, Till
Lehman, William J.
Hardeman, Edna C. http://orcid.org/0000-0003-1649-7712
Gunning, Peter W.
Funding for this research was provided by:
the Australian Department of Industry, Innovation and Science [Cooperative Research Centre-Project Grant CRC-P53981] and TroBio Therapeutics Pty. Ltd.
Article History
Received: 19 June 2019
Accepted: 19 July 2019
First Online: 2 August 2019
Competing Interests
: P.W.G. and E.C.H. declare a commercial interest as directors and shareholders in TroBio Therapeutics Pty Ltd, a company commercializing the use of anti-Tpm drugs. The experiments described in this manuscript were funded by an Australian Department of Industry, Innovation and Science Cooperative Research Centre Project (CRC-P) Grant where TroBio Therapeutics is the Lead Partner. E.E. and J.H. are employed by TroBio Therapeutics, M.J.R. and W.L. were sponsored in part by CRC-P funds and M.J. is employed entirely with CRC-P funds. The author(s) declare no competing non-financial interests.